- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: pancreatic adenocarcinoma.
Displaying page 1 of 1.
EudraCT Number: 2013-003080-59 | Sponsor Protocol Number: GIP-2 | Start Date*: 2013-12-19 | |||||||||||
Sponsor Name:Azienda Ospedaliero-Universitaria Pisana | |||||||||||||
Full Title: PHASE III ITALIAN MULTICENTER STUDY COMPARING THE COMBINATION OF 5-FLUOROURACIL/FOLINIC ACID, OXALIPLATIN AND IRINOTECAN (FOLFOXIRI) VERSUS GEMCITABINE AS ADJUVANT TREATMENT FOR RESECTED PANCREATIC... | |||||||||||||
Medical condition: Stage I-III resected pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005063-29 | Sponsor Protocol Number: GEMOXA001 | Start Date*: 2006-01-01 | |||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
Full Title: Induction Chemotherapy with Gemcitabine-Oxaliplatin GEM-OXA followed by concomitant weekly Gemcitabine plus Radiotherapy GEM/RT in Locally Advanced, Unresectable Pancreatic Cancer A Phase II ... | |||||||||||||
Medical condition: Locally advanced pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005076-26 | Sponsor Protocol Number: SGNTV-001 | Start Date*: 2019-04-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Seagen, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004675-31 | Sponsor Protocol Number: AMCmedonc17-010 | Start Date*: 2019-11-13 |
Sponsor Name:Academic Medical Center | ||
Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs... | ||
Medical condition: pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005314-12 | Sponsor Protocol Number: WX/60-004 | Start Date*: 2007-01-05 | |||||||||||
Sponsor Name:Wilex AG | |||||||||||||
Full Title: A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to ev... | |||||||||||||
Medical condition: Locally advanced, non-resectable pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002551-15 | Sponsor Protocol Number: 8951-CL-5201 | Start Date*: 2019-02-05 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatmen... | |||||||||||||
Medical condition: First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000339-28 | Sponsor Protocol Number: CA025-006 | Start Date*: 2018-10-01 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Advanced Pancreatic Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003086-28 | Sponsor Protocol Number: MM-398-07-02-03 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:Merrimack Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, open-label, Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic... | |||||||||||||
Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000349-14 | Sponsor Protocol Number: CNIS793B12201 | Start Date*: 2020-08-13 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alo... | |||||||||||||
Medical condition: Pancreatic ductal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) FR (Temporarily Halted) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001925-28 | Sponsor Protocol Number: FGCL-3019-087 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanc... | |||||||||||||
Medical condition: Locally Advanced, Unresectable Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Restarted) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001589-85 | Sponsor Protocol Number: D081FC00001 | Start Date*: 2014-11-03 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr... | ||
Medical condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NL (Completed) ES (Ongoing) IT (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002844-10 | Sponsor Protocol Number: CA209-032 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | ||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) FI (Completed) IT (Completed) DK (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003359-13 | Sponsor Protocol Number: 21136 | Start Date*: 2020-12-16 | |||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||
Full Title: A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination with dose in Patients with Recurrent or Metastatic Solid Tumors | |||||||||||||||||||||||
Medical condition: Solid Tumors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003747-37 | Sponsor Protocol Number: MK-7902-005 | Start Date*: 2019-03-07 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) | |||||||||||||
Medical condition: Triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003398-91 | Sponsor Protocol Number: ABI-007-PANC-003 | Start Date*: 2014-05-15 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) HU (Completed) ES (Ongoing) IT (Completed) PT (Completed) BE (Completed) FI (Completed) IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002992-25 | Sponsor Protocol Number: 20140346 | Start Date*: 2019-09-13 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of... | ||||||||||||||||||
Medical condition: gastrointestinal or colorectal adenocarcinoma, which includes cancers of the esophagus, stomach, colon, or rectum. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Trial now transitioned) HU (Prematurely Ended) PT (Trial now transitioned) AT (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003277-42 | Sponsor Protocol Number: MCLA-128-CL01 | Start Date*: 2015-01-13 | |||||||||||
Sponsor Name:Merus B.V. | |||||||||||||
Full Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) PT (Completed) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003585-14 | Sponsor Protocol Number: D-US-60010-001 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Ipsen Bioscience, Inc. | |||||||||||||
Full Title: An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not prev... | |||||||||||||
Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) CZ (Completed) AT (Completed) FR (Completed) PT (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
